Navigation Links
Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe
Date:11/19/2009

MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that the leading driver of antibiotic selection in nosocomial pneumonia in Europe is broad-spectrum activity against gram-positive and gram-negative pathogens. Due to the variety of organisms that can cause nosocomial pneumonia, surveyed European physicians reveal that they look primarily for agents that provide appropriate coverage against common pathogens, particularly for empiric therapy.

"Nosocomial pneumonia is an extremely important indication in Europe because it is a significant cause of morbidity and mortality," stated Decision Resources Analyst Lisa Arias. "Prescribing for nosocomial pneumonia is heavily driven by the need for timely, effective empiric therapy, and European specialists cite Pseudomonas and MRSA as the most concerning pathogens in nosocomial pneumonia."

In the new report entitled Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia, surveyed European infectious disease specialists were highly receptive toward new antibiotics in late-stage development, including the two next-generation anti-MRSA cephalosporins (Johnson & Johnson/Basilea's ceftobiprole and Forest/AstraZeneca's ceftaroline) and the novel anti-MRSA lipoglycopeptide telavancin (Astellas/Theravance/Takeda's Vibativ). European physicians indicate that these therapies could be used in empiric therapy for nosocomial pneumonia when the pathogen is unknown and MRSA infection is suspected. Because European specialists foresee an increase in the incidence of MRSA nosocomial pneumonia in the next five years, these therapies may become useful additions to the antibiotic armamentarium, offering much needed novel treatment options for MRSA nosocomial pneumonia.

"There are limited therapeutic options to target resistant pathogens in nosocomial pneumonia, so there is high unmet need for new, effective therapies in this indication. The broad-spectrum anti-MRSA cephalosporins may offer a convenient monotherapy option for European specialists who would like broad-spectrum nosocomial pneumonia agents possessing activity against troubling pathogens such as MRSA," continued Ms. Arias.

About the Report

AMR and Decision Resources' Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. This report contains European data and examines the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    gmorales@dresources.com                      emarshall@dresources.com

SOURCE Decision Resources; Arlington Medical Resources


'/>"/>
SOURCE Decision Resources; Arlington Medical Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
2. Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate
3. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity
6. Monetary gain and high-risk tactics stimulate activity in the brain
7. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
8. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
9. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
10. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
11. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... ... Asian exhibitions for analytical and scientific instruments. This year’s symposium, organized by the ... in Mass Spectrometry for Bioanalytical Applications.” This dynamic presentation will discuss novel ionization ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... by various biotic and abiotic factors. During this educational webinar, participants will learn ... as well as gain a better understanding of how genomics is important for ...
(Date:8/14/2017)... ... 2017 , ... The Conference Forum has confirmed the one-day agenda ... September 6, 2017 at the Marriott Copley Place in Boston, MA. , Returning as ... Regulatory Strategy, Pfizer Innovative Research Lab, Pfizer, who leads 19 industry speakers in discussing ...
(Date:8/11/2017)... , ... August 11, 2017 , ... ... production, and, in particular, more natural alternatives to synthetic ingredients,” said Matt Hundt, ... Third Wave, with the established manufacturing presence and know-how of Biorigin will allow ...
Breaking Biology Technology:
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) ... international tech event dedicated to developing collaboration between startups and ... on June 15-17. During the event, nine startups will showcase ... value in various industries. France ... the international market, with a 30 percent increase in the ...
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
Breaking Biology News(10 mins):